Wealth Enhancement Trust Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wealth Enhancement Trust Services’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15K	Buy	+450	New	+$11.2K	﹤0.01%	659

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wealth Enhancement Trust Services's RARE Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 450 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #659 among its holdings.

203 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Wealth Enhancement Trust Services held 450 shares of Ultragenyx Pharmaceutical worth $15K as of Q2 2026.
Ultragenyx Pharmaceutical was a new Wealth Enhancement Trust Services position in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #659 holding.
203 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.